14 citations
,
April 2020 in “Journal of Cosmetic Dermatology” In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.
4 citations
,
August 2020 in “Journal of Cosmetic Dermatology” In this study, QR678® and QR678 Neo® injections significantly improved hair density and thickness in women with PCOS-related alopecia over eight sessions, with effects lasting over a year.
3 citations
,
April 2021 in “Journal of Cosmetic Dermatology” Combination therapy with QR 678 Neo and 5% Minoxidil is most effective for male hair loss.
7 citations
,
August 2020 in “Plastic and reconstructive surgery. Global open” In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.
5 citations
,
December 2021 in “Journal of Cosmetic Dermatology” In this study of 20 female patients with Covid-19-induced persistent Telogen Effluvium, intra-dermal QR678 Neo® treatments led to significant reductions in hair fall and increases in hair growth and density, sustained even post-therapy.
